TherapeuticsMD appoints Carr, Riggs & Ingram as auditor

TherapeuticsMD, Inc. has appointed Carr, Riggs & Ingram, L.L.C.

Rhea-AI Filing Summary

TherapeuticsMD, Inc. has appointed Carr, Riggs & Ingram, L.L.C. (CRI) as its new independent registered public accounting firm, effective January 15, 2026. This change follows a transaction in which CRI acquired certain assets related to the capital markets practice of the prior auditor, Berkowitz Pollack Brant Advisors + CPAs (BPB), which has ceased serving as the company’s auditor.

BPB’s audit reports for the fiscal years ended December 31, 2024 and December 31, 2023 did not contain adverse opinions or disclaimers, but they did include an explanatory paragraph about uncertainty regarding the company’s ability to continue as a going concern. The company reports there were no disagreements or reportable events with BPB, and it states that neither it nor its representatives consulted with CRI on accounting or auditing matters before CRI’s appointment.

Insights

Accounting and governance analyst

Auditor changes stem from a practice acquisition, with no reported disputes or new issues.

The company has replaced Berkowitz Pollack Brant Advisors + CPAs with Carr, Riggs & Ingram, L.L.C. as its independent auditor after CRI acquired certain assets related to BPB’s capital markets practice. This frames the auditor change as a consequence of a business transaction between the audit firms rather than a break driven by disputes over accounting or financial reporting.

TherapeuticsMD notes that BPB’s prior audit reports for the 2023 and 2024 fiscal years were clean in terms of opinion type but contained a going concern explanatory paragraph, highlighting uncertainty about the company’s ability to continue as a going concern. The company explicitly states there were no disagreements or reportable events with BPB and that it had not consulted CRI on specific accounting matters before the appointment. Overall, this appears to be an administrative change in audit firm, while the going concern uncertainty remains an important backdrop already disclosed in earlier audited financial statements.

8-K Event Classification

Item 4.01 — Changes in Registrant's Certifying Accountant

1 item

Item 4.01 Changes in Registrant's Certifying Accountant Governance

The company changed its independent auditing firm, which may involve disagreements on accounting matters.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What change in auditor did TherapeuticsMD (TXMD) disclose?

TherapeuticsMD reported that its Audit Committee approved the appointment of Carr, Riggs & Ingram, L.L.C. (CRI) as the company’s independent registered public accounting firm, effective January 15, 2026. Berkowitz Pollack Brant Advisors + CPAs (BPB) ceased serving as auditor after CRI acquired certain assets related to BPB’s capital markets practice.

Why did Berkowitz Pollack Brant (BPB) stop serving as TherapeuticsMD’s auditor?

BPB stopped serving as TherapeuticsMD’s independent registered public accounting firm as a result of a transaction in which Carr, Riggs & Ingram, L.L.C. acquired certain assets related to BPB’s capital markets practice.

Did BPB issue any adverse opinions on TherapeuticsMD’s 2023 or 2024 financial statements?

BPB’s audit reports on TherapeuticsMD’s consolidated financial statements for the fiscal years ended December 31, 2024 and December 31, 2023 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles, other than an explanatory paragraph about going concern.

What going concern issue did TherapeuticsMD’s prior auditor highlight?

BPB’s audit reports for the years ended December 31, 2024 and December 31, 2023 included an explanatory paragraph describing uncertainty about the company’s ability to continue as a going concern, signaling concerns about its future viability that were formally disclosed in those audited financial statements.

Were there any disagreements or reportable events with the prior auditor at TherapeuticsMD?

The company states that during the fiscal years ended December 31, 2025 and December 31, 2024, and through the date of BPB’s dismissal, there were no disagreements on accounting principles, financial statement disclosure, or auditing scope or procedure, and no reportable events as defined under Regulation S-K.

Did TherapeuticsMD consult with Carr, Riggs & Ingram before appointing them as auditor?

TherapeuticsMD reports that during the years ended December 31, 2025 and December 31, 2024 and through the date of CRI’s appointment, neither the company nor anyone acting on its behalf consulted with CRI on the application of accounting principles, potential audit opinions, or any matters that would have been disagreements or reportable events.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/20/2026 - 05:43 PM Learn about SEC filing dates

false 0000025743 0000025743 2026-01-15 2026-01-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): January 15, 2026

THERAPEUTICSMD, INC. 

(Exact Name of Registrant as Specified in its Charter)

Nevada		001-00100		87-0233535
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

951 Yamato Road, Suite 220

Boca Raton, FL 33431

(Address of Principal Executive Office) (Zip Code)

Registrant’s telephone number, including area code: (561) 961-1900

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share		TXMD		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230-405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 4.01 Changes in Registrant’s Certifying Accountant.

On January 15, 2026, the Audit Committee of the Board of Directors of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), approved the appointment of Carr, Riggs & Ingram, L.L.C. (“CRI”) as the Company’s independent registered public accounting firm, effective immediately. In connection therewith, Berkowitz Pollack Brant Advisors + CPAs (“BPB”), the Company’s prior independent registered public accounting firm, ceased serving as the Company’s independent registered public accounting firm as a result of a transaction pursuant to which CRI acquired certain assets related to the capital markets practice of BPB.

BPB’s audit reports on the Company’s consolidated financial statements for each of the fiscal years ended December 31, 2024 and December 31, 2023 did not contain an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles, except that BPB’s reports on the Company’s financial statements as of and for the fiscal years ended December 31, 2024 and December 31, 2023 included an explanatory paragraph describing the uncertainty of the Company’s ability to continue as a going concern.

During the Company’s fiscal years ended December 31, 2025 and December 31, 2024 through the date of dismissal: (1) there were no “disagreements” (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304) with BPB on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of BPB, would have caused BPB to make reference to the subject matter of such disagreements in connection with its reports on the financial statements for such periods, and (2) there were no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K).

The Company provided BPB with a copy of this Current Report on Form 8-K (this “Report”) prior to its filing with the Securities and Exchange Commission (the “SEC”) and requested that BPB furnish the Company with a letter addressed to the SEC stating whether BPB agrees with the statements made by the Company in this Report and, if not, stating the respects, if any, in which BPB does not agree with such statements. The letter of BPB addressed to the Securities and Exchange Commission is attached hereto as Exhibit 16.1.

During the years ended December 31, 2025 and December 31, 2024 and through the date of their appointment, neither the Company nor anyone acting on its behalf consulted with CRI regarding: (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that CRI concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a “disagreement” within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 or a “reportable event” within the meaning of Item 304(a)(1)(v) of Regulation S-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Index

Exhibit No.		Description
16.1		Letter from Berkowitz Pollack Brant Advisors + CPAs to the Securities and Exchange Commission, dated January 20, 2026.
104		Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 20, 2026	THERAPEUTICSMD, INC.
	/s/ Marlan Walker
	Marlan Walker
	Chief Executive Officer

2